Bifidobacterium longum subsp. longum CCFM1375 Mitigates Chronic Kidney Disease Progression via Gut Microbiota Modulation and Gut Barrier Restoration

Chronic kidney disease (CKD) is associated with impaired kidney function, intestinal barrier dysfunction, accumulation of uremic toxins, and gut microbiota dysbiosis. In this study, we used an adenine‐induced CKD mouse model to evaluate the effects of Bifidobacterium longum subsp. longum CCFM1375 on CKD progression. Mice with CKD displayed increased serum creatinine and blood urea nitrogen (BUN) levels, kidney tissue histopathological injury, disrupted intestinal barrier integrity, elevated lipopolysaccharides (LPS) levels, and changes in gut microbiota composition. Intervention with B. longum subsp. longum CCFM1375 significantly alleviated these symptoms. Bifidobacterium longum subsp. longum CCFM1375 enhanced gut barrier function by upregulating tight junction proteins (ZO‐1, ZO‐2) and reducing pro‐inflammatory cytokines (IL‐6, TNF‐α), thereby lowering serum LPS levels. Metagenomic analysis revealed that B. longum subsp. longum CCFM1375 restored the gut microbial structure, increasing beneficial species such as Faecalibaculum rodentium, Asaccharobacter celatus, Adlercreutzia equolifaciens, while reducing potential pathogens. Furthermore, metabolic analysis showed that gut microbiota metabolic functions shifted from urea production to amino acid biosynthesis, significantly increasing fecal tryptophan and tyrosine levels and elevating serum glutamate content, potentially alleviating CKD progression by reducing urea production and ammonia toxicity. The intervention also enhanced thiamine synthesis and increased fecal cholic acid levels, significantly reducing serum uremic toxin levels, including trimethylamine N‐oxide, phenyl sulfate, and the indoleacetic acid precursor indole‐3‐pyruvic acid. In conclusion, B. longum subsp. longum CCFM1375 may delay CKD progression by repairing the intestinal barrier, modulating nitrogen metabolism pathways, and reducing uremic toxin accumulation, providing new evidence for the use of probiotics in kidney disease intervention.

• Publication year

  2025

• Venue

  Food Frontiers

• Publication date

  2025-10-16

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1002/fft2.70119
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Acute Pyelonephritis with Bacteremia in an 89-Year-Old Woman Caused by Two Slow-Growing Bacteria: Aerococcus urinae and Actinotignum schaalii

  2023cited by this paper
• Prevalence of Chronic Kidney Disease in China: Results From the Sixth China Chronic Disease and Risk Factor Surveillance.

  2023cited by this paper
• Engineering of Shikimate Pathway and Terminal Branch for Efficient Production of L-Tryptophan in Escherichia coli

  2023cited by this paper
• Gut Microbiota as a Source of Uremic Toxins

  2022cited by this paper
• Association of equol producing status with aortic calcification in middle-aged Japanese men: The ERA JUMP study.

  2022cited by this paper
• Inflammation in Children with CKD Linked to Gut Dysbiosis and Metabolite Imbalance

  2022cited by this paper
• Comparative Genomics Analyses Reveal the Differences between B. longum subsp. infantis and B. longum subsp. longum in Carbohydrate Utilisation, CRISPR-Cas Systems and Bacteriocin Operons

  2021cited by this paper
• The effect of probiotic supplementation on systemic inflammation in dialysis patients

  2021cited by this paper
• The probiotic L. casei Zhang slows the progression of acute and chronic kidney disease.

  2021cited by this paper
• Comprehensive metabolomics profiling reveals common metabolic alterations underlying the four major non-communicable diseases in treated HIV infection

  2021cited by this paper
• Integrative metagenomic and metabolomic analyses reveal severity-specific signatures of gut microbiota in chronic kidney disease

  2020cited by this paper
• TMAO: How gut microbiota contributes to heart failure.

  2020cited by this paper
• Alterations of the Human Gut Microbiome in Chronic Kidney Disease

  2020cited by this paper
• Ameliorate effects of soybean soluble polysaccharide on adenine-induced chronic renal failure in mice.

  2020cited by this paper
• Isolation and Quantification of Uremic Toxin Precursor-Generating Gut Bacteria in Chronic Kidney Disease Patients

  2020cited by this paper
• Daidzein Intake Is Associated with Equol Producing Status through an Increase in the Intestinal Bacteria Responsible for Equol Production

  2019cited by this paper
• A ropy exopolysaccharide producing strain Bifidobacterium longum subsp. longum YS108R alleviates DSS-induced colitis by maintenance of the mucosal barrier and gut microbiota modulation.

  2019cited by this paper
• Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease.

  2018cited by this paper
• Intestinal barrier disruption and dysregulated mucosal immunity contribute to kidney fibrosis in chronic kidney disease

  2018cited by this paper
• Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update

  2018cited by this paper
• A novel approach to adenine-induced chronic kidney disease associated anemia in rodents

  2018cited by this paper
• Being overweight or obese is associated with harboring a gut microbial community not capable of metabolizing the soy isoflavone daidzein to O-desmethylangolensin in peri- and post-menopausal women.

  2017cited by this paper
• Homeostasis of the gut barrier and potential biomarkers

  2016cited by this paper
• Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY): A Randomized Trial.

  2016cited by this paper
• Aerococcus: an increasingly acknowledged human pathogen.

  2016cited by this paper
• The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients: a randomised, double-blind, placebo-controlled trial.

  2015cited by this paper
• Impact of equol-producing capacity and soy-isoflavone profiles of supplements on bone calcium retention in postmenopausal women: a randomized crossover trial.

  2015cited by this paper
• Trimmomatic: a flexible trimmer for Illumina sequence data

  2014cited by this paper
• The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease.

  2013cited by this paper
• Hippurate: the natural history of a mammalian-microbial cometabolite.

  2013cited by this paper
• Normal and pathologic concentrations of uremic toxins.

  2012cited by this paper
• Valproic acid attenuates proteinuria and kidney injury.

  2011cited by this paper
• The Sequence Alignment/Map format and SAMtools

  2009cited by this paper
• Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis.

  2003cited by this paper
• Creatine and creatinine metabolism.

  2000cited by this paper
• Bioinformatics Applications Note Genome Analysis Bedtools: a Flexible Suite of Utilities for Comparing Genomic Features

  year unknowncited by this paper

• No citing papers are available for this paper.